Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Enterprise Value (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Enterprise Value for 7 consecutive years, with -$4.6 million as the latest value for Q3 2025.

  • For Q3 2025, Enterprise Value fell 59.05% year-over-year to -$4.6 million; the TTM value through Sep 2025 reached -$4.6 million, down 59.05%, while the annual FY2024 figure was -$3.2 million, 57.31% up from the prior year.
  • Enterprise Value hit -$4.6 million in Q3 2025 for Cyclerion Therapeutics, down from -$3.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$2.9 million in Q3 2024 and bottomed at -$70.4 million in Q2 2021.
  • Average Enterprise Value over 5 years is -$20.6 million, with a median of -$7.6 million recorded in 2023.
  • Year-over-year, Enterprise Value skyrocketed 82.56% in 2023 and then tumbled 59.05% in 2025.
  • Cyclerion Therapeutics' Enterprise Value stood at -$54.0 million in 2021, then soared by 75.2% to -$13.4 million in 2022, then soared by 43.42% to -$7.6 million in 2023, then soared by 57.31% to -$3.2 million in 2024, then plummeted by 41.34% to -$4.6 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$4.6 million, -$3.0 million, and -$3.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.